About entrectini b
TRK and ROS1 kinase inhibitor
Used for
- Treats certain advanced solid tumors with an NTRK gene fusion.
- Treats ROS1-positive non-small-cell lung cancer.
Usual adult dose
600 mg by mouth once daily; dosing may be adjusted for side effects or interactions.
Usual dose in children
For NTRK fusion-positive tumors: 300 mg/m² by mouth once daily, maximum 600 mg; specialist-directed dosing.
Common side effects
- Fatigue, dizziness, or changes in taste
- Constipation, diarrhea, nausea, or vomiting
- Swelling, weight gain, or muscle pain
- Anemia or other abnormal blood tests
Important warnings
- May cause heart failure, abnormal heart rhythm, or QT prolongation.
- Can cause dizziness, confusion, or other nervous-system effects.
- May cause liver problems, fractures, or vision changes.
- Avoid driving if dizzy; pregnancy prevention may be needed during treatment.
Pregnancy
May harm an unborn baby. Avoid during pregnancy; effective contraception is recommended during treatment and for 5 weeks after the last dose.
Breastfeeding
Avoid breastfeeding during treatment and for 1 week after the last dose.
Interactions
- Strong or moderate CYP3A inhibitors can raise entrectinib levels.
- Strong or moderate CYP3A inducers can reduce effectiveness.
- Avoid grapefruit and Seville oranges, which can increase drug levels.
- May interact with medicines that prolong the QT interval.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.